Skip to main content

Table 2 Demographic and clinical characteristics of RA patients according to BMI

From: Serum leptin and serum leptin/serum leptin receptor ratio imbalance in obese rheumatoid arthritis patients positive for anti-cyclic citrullinated peptide antibodies

Measurement All Normal weight Preobese Obese
BMI 18.50–24.99 kg/m2 BMI 25.00–29.99 kg/m2 BMI ≥30.00 kg/m2
n = 64 n = 21 n = 21 n = 22
Female gender, n (%) 60 (93.8) 19 (90.5) 20 (95.2) 21 (95.5)
Time of disease evolution, years 5.34 ± 6.97 5.73 ± 8.95 5.06 ± 4.80 5.23 ± 6.78
Positive anti-CCP, n (%) 46 (71.9) 15 (71.4) 13 (61.9) 18 (81.8)
Anti-CCP, U/Ml 167.20 ± 305.49 179.03 ± 405.53 218.45 ± 338.76 107.00 ± 86.53
Positive RF, n (%) 41 (65.1) 13 (61.9) 15 (71.4) 13 (61.9)
RF, UI/Ml 79.39 ± 51.57 93.03 ± 43.26 79.65 ± 60.09 68.01 ± 47.61
ESR, mm/h 21.27 ± 12.74 19.38 ± 9.82 17.10 ± 12.14 27.33 ± 14.08b
CRP, mg/L 9.14 ± 7.71 7.66 ± 7.08 8.83 ± 6.67 11.02 ± 9.19
DAS-28-based CRP 3.40 ± 1.30 2.90 ± 1.20 3.82 ± 1.24 3.53 ± 1.36
TNFα, pg/Ml 57.05 ± 39.87 62.03 ± 34.40 60.93 ± 53.82 48.83 ± 27.48
sLep, ng/Ml 119.70 ± 104.64 45.98 ± 40.26a 121.65 ± 106.35 188.21 ± 100.88
sLepR, ng/Ml 50.45 ± 17.25 60.02 ± 18.81c 51.34 ± 12.51 37.49 ± 9.67
sLep/sLepR, ng/mL 2.87 ± 3.19 0.98 ± 1.40a 2.45 ± 2.45 5.67 ± 3.56
Insulin resistance, n (%) 18 (36.7) 5 (26.3) 5 (35.7) 8 (50.0)
  1. Continuous variables are represented as mean ± standard deviation; qualitative variables are represented as number (%). Groups were compared with one-way analysis of variance and Dunnet’s T3 post hoc test. aNormal weight vs. preobese and obese; bpreobese vs. obese; cNormal weight vs. obese. BMI body mass index, anti-CCP anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor, ESR erythrocyte sedimention rate, CRP C-Reactive protein, TNF tumor necrosis factor, sLep soluble leptin), sLepR soluble leptin receptor, HOMA-IR homeostatic model assessment, DAS-28 disease activity index in 28 joints